The Revenue Rises
  • Politics
  • Stocks
  • Business
  • Economy
Trending Now
S&P 500 Earnings for 2025 Q1 — Still...
Money’s Not Leaving the Market — It’s Rotating!
From Oversold to Opportunity: Small Caps on the...
Tariffs and weaker beer demand are weighing on...
Essence Fest leads a summer of events for...
Pullbacks & Reversals: Stocks Setting Up for Big...
S&P 500 Earnings for 2025 Q1 — Still...
Market Signals Align – Is a Bigger Move...
MACD Crossovers: Why Most Traders Get It Wrong
Should You Buy Roblox Stock Now? Key Levels...

The Revenue Rises

  • Politics
  • Stocks
  • Business
  • Economy
Business

Lawmakers ask Mark Zuckerberg to show how Facebook, Instagram are addressing illicit drug ads

by admin August 17, 2024
August 17, 2024
Lawmakers ask Mark Zuckerberg to show how Facebook, Instagram are addressing illicit drug ads

A bipartisan group of lawmakers sent Meta CEO Mark Zuckerberg a letter on Thursday expressing concern that the company is failing to prevent illicit drug advertisements from running on its platform.

The House members cited recent reports from The Wall Street Journal and nonprofit Tech Transparency Project, which uncovered a flood of ads on Facebook and Instagram that pointed users to third-party services where they could purchase prescription pills, cocaine and other recreational drugs.

“On March 16, 2024, the Wall Street Journal reported that U.S. federal prosecutors have been investigating Meta for facilitating the sale of illicit drugs,” the lawmakers wrote. “Instead of quickly addressing the issue and fully removing the illicit content, on July 31, 2024, the Wall Street Journal again reported that Meta was ‘“running ads on Facebook and Instagram that steer users to online marketplaces for illegal drugs.’”

Most troubling, they wrote, is that Meta continues to run ads despite the company facing an investigation by U.S. federal prosecutors “for facilitating the sale of illicit drugs.”

The letter’s 19 authors include Reps. Tim Walberg (R-Mich.), Gus Bilirakis (R-Fla.), Kathy Castor (D-Fla.) and Lori Trahan (D-Mass.). They noted that the illicit drug ads were “approved and monetized by Meta” and that they were not hidden on the dark web or private social media pages. Media outlets and researchers could easily find the ads, which contained “contained blatant references to illegal drugs,” while Meta’s internal processes apparently missed them.

“Time and time again we have heard from Meta that users come to your platforms because they like the personalization and experiences you provide, and you use sensitive personal information to direct such personalization through content and advertisements,” the lawmakers wrote. “We in Congress, on multiple occasions, have worked to establish data privacy and security protections for Americans but have, in each instance, been met with friction and opposition from Meta with claims that we would drastically disrupt this personalization you are providing.”

They sent Zuckerberg a list of 15 questions intended to uncover more details about how Meta is addressing the problem, and asked him to respond by Sept. 6.

Meta confirmed receipt of the letter and said it plans to respond. The company shared with CNBC the same statement it gave the Journal for its initial story.

“Drug dealers are criminals who work across platforms and communities, which is why we work with law enforcement to help combat this activity. Our systems are designed to proactively detect and enforce against violating content, and we reject hundreds of thousands of ads for violating our drug policies. We continue to invest resources and further improve our enforcement on this kind of content. Our hearts go out to those suffering from the tragic consequences of this epidemic — it requires all of us to work together to stop it.”

This post appeared first on NBC NEWS

previous post
CRITICAL Week Ahead for S&P 500
next post
Secret Service boosts protection for Trump and Harris

Related Posts

PepsiCo to buy tortilla chip maker Siete Foods...

October 3, 2024

‘Wicked’ tallies $19M in previews, as ‘Gladiator II’...

November 25, 2024

Digital health companies pummeled by Wall Street in...

December 27, 2024

First the token, now the swipe: NYC’s subway...

March 20, 2025

Last-minute summer travelers are finding the best deals...

August 13, 2024

Bronfman’s Paramount bid could keep Shari Redstone involved...

August 27, 2024

OpenAI announces a search engine called SearchGPT; Alphabet...

July 27, 2024

UAW union endorses Vice President Kamala Harris over...

August 2, 2024

Reddit targets international users for ad growth, teases...

November 28, 2024

Major maritime strike could threaten ports across the...

September 22, 2024

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Recent Posts

    • S&P 500 Earnings for 2025 Q1 — Still Overvalued
    • Money’s Not Leaving the Market — It’s Rotating!
    • From Oversold to Opportunity: Small Caps on the Move
    • Tariffs and weaker beer demand are weighing on Modelo owner Constellation Brands
    • Essence Fest leads a summer of events for Black entrepreneurs galvanized by economic uncertainty

    Popular Posts

    • 1

      Polls show some good early signs for Kamala Harris

      July 26, 2024
    • 2

      Solana and Cardano: Solana is waiting for a new impulse

      July 18, 2024
    • 3

      The presidential race shifts — modestly, so far — toward Harris

      August 6, 2024
    • 4

      Donald Trump’s imaginary and frightening world

      September 23, 2024
    • 5

      Bitcoin Rebounds to $83,404 Amid Renewed Investor Confidence

      June 4, 2025

    Categories

    • Business (729)
    • Economy (975)
    • Politics (873)
    • Stocks (867)
    • About us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: therevenuerises.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 The Revenue Rises. All Rights Reserved.